Impact of Thymosin α1 as an Immunomodulatory Therapy on Long-Term Survival of Non-Small Cell Lung Cancer Patients After R0 Resection: A Propensity Score-Matched Analysis
Non-small cell lung cancer (NSCLC) remains one of the most prevalent and lethal malignancies worldwide, with surgical resection being a cornerstone of curative treatment. However, even after achieving an R0 resection (complete removal of the tumor with negative margins), a significant proportion of patients experience disease recurrence and mortality. The search for effective adjuvant therapies to improve long-term survival outcomes has led to the exploration of immunomodulatory agents, such as thymosin α1 (Tα1). This study investigates the impact of Tα1 on disease-free survival (DFS) and overall survival (OS) in NSCLC patients following R0 resection, employing a propensity score-matched analysis to mitigate confounding factors.
Thymosin α1 is a naturally occurring peptide with potent immunomodulatory properties. It enhances T-cell function, promotes dendritic cell maturation, and modulates cytokine production, thereby bolstering the body’s immune response against cancer. Given its ability to restore immune homeostasis, Tα1 has been investigated as a potential adjuvant therapy in various malignancies, including NSCLC. This study aimed to evaluate its efficacy in improving survival outcomes in a cohort of NSCLC patients who underwent R0 resection.
The study included patients diagnosed with NSCLC who underwent curative-intent R0 resection at a single institution. Patients were stratified based on the duration of Tα1 administration: less than 12 months, 12–24 months, and more than 24 months. Propensity score matching was employed to balance baseline characteristics between the groups, ensuring a more robust comparison of outcomes. The primary endpoints were DFS and OS, analyzed using Kaplan-Meier survival curves and Cox proportional hazards models.
The results demonstrated a significant association between the duration of Tα1 administration and improved survival outcomes. In the analysis of DFS, patients who received Tα1 for 12–24 months had a hazard ratio (HR) of 0.463 (95% confidence interval [CI]: 0.341–0.683, P = 0.0001) compared to those who received it for less than 12 months. For patients who received Tα1 for more than 24 months, the HR was 0.284 (95% CI: 0.197–0.409, P < 0.0001). Additionally, the HR for DFS in the 12–24 months group compared to the more than 24 months group was 1.632 (95% CI: 1.056–2.522, P = 0.0275), indicating a progressive benefit with longer duration of therapy.
Similarly, in the analysis of OS, the HR for patients receiving Tα1 for 12–24 months was 0.357 (95% CI: 0.216–0.588, P < 0.0001) compared to those receiving it for less than 12 months. For patients treated for more than 24 months, the HR was 0.171 (95% CI: 0.107–0.272, P < 0.0001). The HR for OS in the 12–24 months group compared to the more than 24 months group was 2.090 (95% CI: 1.175–3.717, P = 0.0121), further underscoring the survival advantage associated with prolonged Tα1 administration.
The Kaplan-Meier curves for both DFS and OS illustrated a clear separation between the groups, with longer durations of Tα1 therapy correlating with improved survival. These findings suggest that Tα1, as an immunomodulatory adjuvant therapy, can significantly enhance long-term outcomes in NSCLC patients following R0 resection. The study’s use of propensity score matching strengthens the validity of these results by minimizing the influence of confounding variables.
The mechanisms underlying the beneficial effects of Tα1 in NSCLC are multifaceted. By enhancing T-cell activity and promoting dendritic cell maturation, Tα1 likely augments the immune system’s ability to detect and eliminate residual cancer cells post-resection. Additionally, its ability to modulate cytokine production may create a tumor microenvironment less conducive to cancer progression and recurrence. These immunomodulatory effects, coupled with its favorable safety profile, make Tα1 a promising candidate for adjuvant therapy in NSCLC.
The study also highlights the importance of treatment duration in achieving optimal outcomes. The progressive reduction in hazard ratios with longer durations of Tα1 administration suggests that sustained immunomodulation is critical for maximizing survival benefits. This finding has important implications for clinical practice, as it underscores the need for adherence to prolonged Tα1 therapy in eligible patients.
In conclusion, this study provides compelling evidence for the efficacy of thymosin α1 as an immunomodulatory adjuvant therapy in improving long-term survival outcomes in NSCLC patients following R0 resection. The significant reductions in hazard ratios for both DFS and OS, particularly with prolonged administration, highlight the potential of Tα1 to address the unmet need for effective adjuvant therapies in this patient population. These findings warrant further investigation in larger, randomized controlled trials to confirm the benefits of Tα1 and to refine its role in the management of NSCLC.
doi.org/10.1097/CM9.0000000000001819
Was this helpful?
0 / 0